Common genetic variants associated with development of high-risk neuroblastoma

September 19, 2011

Patients with a high degree of African ancestry had a greater incidence of high-risk neuroblastoma and poorer outcomes, according to preliminary results presented here at the Fourth AACR Conference on The Science of Cancer Health Disparities, held here Sept. 18-21, 2011.

"There are common genetic variants that are associated with the development of high-risk neuroblastoma and a poor outcome," said Navin R. Pinto, M.D., instructor of pediatrics at the University of Chicago in Chicago, Ill. "These variants are more common in patients of African origin, but have the potential to be present and affect patients of all ethnic backgrounds. Identifying patients with these variants at the time of diagnosis may one day allow us to modify treatment for those who are genetically at risk for with standard therapies."

Neuroblastoma is a with a widely variable clinical outcome, Pinto said. Some children do well with no therapy, while others die despite aggressive chemotherapy, surgery, and immunotherapy.

In a previous study of 3,539 children with neuroblastoma, Pinto and colleagues found that patients who self-reported as black were much more likely to have high-risk disease and have an increased incidence of late relapses, suggesting that germline linked with ethnicity or ancestry may influence disease development.

For this follow-up study of 3,508 racially mixed children with neuroblastoma, the researchers obtained germline genotypes from investigators at the Children's Hospital of Philadelphia. They then created an ancestral map using the patients' genotypes and the publicly available genotypes of three ancestral populations: African, Asian and white.

Children with a higher degree of African ancestry had increased rates of high-risk disease and lower following chemotherapy, according to the study's preliminary findings.

"This indicates that African ancestors may have passed along common genetic variants that are associated with the development of the aggressive form of neuroblastoma and perhaps a relative intrinsic chemotherapy resistance that is associated with the observed inferior outcomes," Pinto said.

Armed with these findings, researchers can now focus on the specific genetic variants linked with inferior outcome, Pinto said. These variants may be found in patients of any ethnic makeup, not just .

"The remarkable improvements in cure rates for childhood malignancies over the past 50 years have, in large part, come from recognizing clinical or biological features that are associated with a poor outcome and intensifying therapy for patients at high risk of non-response," Pinto said. "Germline genetic variables will likely one day be included in risk stratification algorithms for the treatment of neuroblastoma. I believe we are on the cusp of discovering these variants."

Explore further: New genetic risk factors of lupus found in study of African-American women

Related Stories

New genetic risk factors of lupus found in study of African-American women

June 24, 2011
Researchers from Boston University's Slone Epidemiology Center have found four new genetic variants in the major histocompatibility complex (MHC) that confer a higher risk of systemic lupus erythemathosus ("lupus") in African ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.